These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32549017)

  • 1. [All women should participate in the Norwegian Breast Cancer Screening Programme].
    Torgersen JGR; Andreassen T; Janbu T
    Tidsskr Nor Laegeforen; 2020 Jun; 140(9):. PubMed ID: 32549017
    [No Abstract]   [Full Text] [Related]  

  • 2. [Misleading and tendentious comments about information in the Norwegian Breast Cancer Screening Programme].
    Hofvind S; Mangerud G; Ursin G
    Tidsskr Nor Laegeforen; 2020 Apr; 140(6):. PubMed ID: 32321230
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer incidence trends in Norway and estimates of overdiagnosis.
    van Luijt PA; Heijnsdijk EA; van Ravesteyn NT; Hofvind S; de Koning HJ
    J Med Screen; 2017 Jun; 24(2):83-91. PubMed ID: 27754936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Do women receive enough information to make informed choices about breast cancer screening?].
    Hofmann B
    Tidsskr Nor Laegeforen; 2020 Feb; 140(3):. PubMed ID: 32105039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program.
    Hofvind S; Román M; Sebuødegård S; Falk RS
    J Med Screen; 2016 Dec; 23(4):203-209. PubMed ID: 26940960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the Norwegian breast cancer screening program.
    van Luijt PA; Heijnsdijk EA; de Koning HJ
    Int J Cancer; 2017 Feb; 140(4):833-840. PubMed ID: 27861849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RE: Breast Cancer Mortality After Implementation of Organized Population-Based Screening in Norway.
    Zahl PH
    J Natl Cancer Inst; 2020 Nov; 112(11):1174. PubMed ID: 32986840
    [No Abstract]   [Full Text] [Related]  

  • 8. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program.
    Kalager M; Adami HO; Bretthauer M; Tamimi RM
    Ann Intern Med; 2012 Apr; 156(7):491-9. PubMed ID: 22473436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of organized mammography screening on breast cancer mortality: A population-based cohort study in Norway.
    Møller MH; Lousdal ML; Kristiansen IS; Støvring H
    Int J Cancer; 2019 Feb; 144(4):697-706. PubMed ID: 30144028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway.
    Kalager M; Løberg M; Bretthauer M; Adami HO
    Ann Oncol; 2014 Jun; 25(6):1137-43. PubMed ID: 24669012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer mortality in Norway after the introduction of mammography screening.
    Olsen AH; Lynge E; Njor SH; Kumle M; Waaseth M; Braaten T; Lund E
    Int J Cancer; 2013 Jan; 132(1):208-14. PubMed ID: 22532175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Attendance in the Norwegian Breast Cancer Screening Programme].
    Sebuødegård S; Sagstad S; Hofvind S
    Tidsskr Nor Laegeforen; 2016 Sep; 136(17):1448-51. PubMed ID: 27686204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening?
    Hofvind S; Sakshaug S; Ursin G; Graff-Iversen S
    Int J Cancer; 2012 Jun; 130(12):2930-8. PubMed ID: 21732346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening outcome for consecutive examinations with digital breast tomosynthesis versus standard digital mammography in a population-based screening program.
    Hovda T; Brandal SHB; Sebuødegård S; Holen ÅS; Bjørndal H; Skaane P; Hofvind S
    Eur Radiol; 2019 Dec; 29(12):6991-6999. PubMed ID: 31187221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower attendance rates in immigrant versus non-immigrant women in the Norwegian Breast Cancer Screening Programme.
    Bhargava S; Tsuruda K; Moen K; Bukholm I; Hofvind S
    J Med Screen; 2018 Sep; 25(3):155-161. PubMed ID: 29059006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overdiagnosis in mammography screening].
    Zahl PH; Maehlen J
    Tidsskr Nor Laegeforen; 2004 Sep; 124(17):2238-9. PubMed ID: 15356688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic breast cancer in non-participants of the national screening programme in Norway: a confounding factor in evaluation?
    Hoff SR; Klepp O; Hofvind S
    J Med Screen; 2012 Dec; 19(4):177-83. PubMed ID: 23486698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
    Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No difference in the prevalence of benign breast changes between women from Ghana and Norway: an autopsy study.
    Stalsberg H; Adjei EK; Owusu-Afriyie O
    Breast Cancer Res Treat; 2015 May; 151(1):177-82. PubMed ID: 25893589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Screening for breast cancer: worries about its effectiveness].
    Autier P
    Rev Prat; 2013 Dec; 63(10):1369-77. PubMed ID: 24579331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.